Treatment of psoriatic arthropathy with etretinate: a two-year follow-up
DOI:
https://doi.org/10.2340/0001555566321324Abstract
In psoriatic arthropathy the data obtained after two years of etretinate treatment in 20 adult male patients, are reported. The beneficial effects of the drug on the objective symptoms are accompanied by an improvement in the biohumoral parameters evaluated. The dose was 1 mg/kg/day for one month, with subsequent adjustments in relation to the results obtained with a maintenance dose of 25 mg/day, or where possible, 10 mg/day, or on alternate days, for a maximum period of 25 months. The side effects appeared to be of an acceptable degree of severity. The authors consider etretinate one of the drugs of first choice in the treatment of psoriatic arthropathy.Downloads
Download data is not yet available.
Downloads
Published
1986-07-01
How to Cite
Chieregato, G., & Leoni, A. (1986). Treatment of psoriatic arthropathy with etretinate: a two-year follow-up. Acta Dermato-Venereologica, 66(4), 321–324. https://doi.org/10.2340/0001555566321324
Issue
Section
Articles
License
Copyright (c) 1986 Acta Dermato-VenereologicaAll digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
